Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 53, 2018 - Issue 2
Submit an article Journal homepage
1,250
Views
24
CrossRef citations to date
0
Altmetric
Original Article

High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab – a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO)*

Tero Ylisaukko-ojaTakeda Oy, Helsinki, Finland; ;MedEngine Oy, Helsinki, Finland; ;Faculty of Medicine, Center for Life Course Health Research University of Oulu, Oulu, Finland; Correspondence[email protected]
View further author information
,
Jaakko AaltonenTakeda Oy, Helsinki, Finland; View further author information
,
Heikki NuutinenDivision of Gastroenterology, Department of Medicine, Turku University Hospital, Turku, Finland; View further author information
,
Timo BlomsterDivision of Gastroenterology, Department of Medicine, Oulu University Hospital, Oulu, Finland; View further author information
,
Airi JussilaDepartment of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Tampere, Finland; View further author information
,
Markku PajalaDepartment of Internal Medicine, Kuopio University Hospital, Kuopio, Finland; View further author information
,
Kimmo SalminenDivision of Gastroenterology, Department of Medicine, Turku University Hospital, Turku, Finland; View further author information
,
Veikko MoilanenDepartment of Internal Medicine, Satakunta Central Hospital, Pori, Finland; View further author information
,
Kalle HakalaDepartment of Internal Medicine, Kanta-Häme Central Hospital, Hämeenlinna, Finland; View further author information
,
Mikko KellokumpuDepartment of Internal Medicine, Lapland Central Hospital, Rovaniemi, Finland; View further author information
,
Kari ToljamoDepartment of Internal Medicine, TYKS Salo Hospital, Salo, Finland; View further author information
,
Henna RautiainenDepartment of Gastroenterology, Helsinki University Hospital/Jorvi Hospital, Espoo, Finland; View further author information
,
Juha KuismaDepartment of Internal Medicine, HUS Hyvinkää Hospital, Hyvinkää, Finland; View further author information
,
Markku PeräahoDepartment of Internal Medicine, Central Hospital of Central Finland, Jyväskylä, Finland; View further author information
,
Pauliina MolanderDepartment of Gastroenterology, Helsinki University Hospital/Peijas Hospital, Vantaa, Finland; View further author information
,
Jouni SilvennoinenDepartment of Gastroenterology, North Karelia Central Hospital, Joensuu, Finland; View further author information
,
Ville LiukkonenDepartment of Gastroenterology, North Karelia Central Hospital, Joensuu, Finland; View further author information
,
Hans HenricsonDepartment of Internal Medicine, Hospital Pietarsaari, Pietarsaari, Finland; View further author information
,
Jyrki TillonenDepartment of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland; View further author information
,
Mirva EsterinenDepartment of Internal Medicine, Savonlinna Central Hospital, Savonlinna, Finland; View further author information
,
Christian NielsenDepartment of Internal Medicine, Vaasa Central Hospital, Vaasa, Finland; View further author information
,
Eija HirsiDepartment of Internal Medicine, South Karelia Central Hospital, Lappeenranta, Finland; View further author information
,
Margus LääneDepartment of Internal Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland; View further author information
,
Ulla-Maija SuhonenDepartment of Internal Medicine, Kainuu Central Hospital, Kajaani, Finland; View further author information
,
Ilkka VihriäläDepartment of Internal Medicine, Central Ostrobothnia Central Hospital, Kokkola, Finland; View further author information
,
Petri MäkeläDepartment of Internal Medicine, Turku City Hospital, Turku, Finland; View further author information
,
Mika PuhtoDepartment of Internal Medicine, Mikkeli Central Hospital, Mikkeli, Finland; View further author information
,
Jari PunkkinenDepartment of Internal Medicine, HUS Porvoo Hospital, Porvoo, Finland; View further author information
,
Hannu SulonenDepartment of Internal Medicine, Forssa Hospital, Forssa, Finland; View further author information
,
Sauli HerralaMedEngine Oy, Helsinki, Finland; View further author information
,
Jari JokelainenMedEngine Oy, Helsinki, Finland; ;Faculty of Medicine, Center for Life Course Health Research University of Oulu, Oulu, Finland; ;Unit of Primary Health Care, Oulu University Hospital, Oulu, Finland; View further author information
,
Klaus TamminenTakeda Oy, Helsinki, Finland; View further author information
&
Taina SipponenDepartment of Gastroenterology, Helsinki University Hospital and University of Helsinki, Helsinki, FinlandView further author information
 show all
Pages 158-167 | Received 11 Nov 2017, Accepted 05 Dec 2017, Published online: 19 Dec 2017

Citations (24)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Jonathan R. White, Said Din, Richard J. M. Ingram, Stephen Foley, Mohammad Aftab Alam, Richard Robinson, Rodric Francis, Emily Tucker, Mustafa Jalal, David Elphick, Edmond Atallah, Anthony Norman, Muhammad Amin, Aamir Sajjad, Nicola Heggs, Simon Meadowcroft & Gordon W. Moran. (2020) Experiences of using vedolizumab in the treatment of inflammatory bowel disease in the East Midlands UK – a retrospective observational study. Scandinavian Journal of Gastroenterology 55:8, pages 907-916.
Read now
Ciaran Judge, Neasa McGettigan, Timothy Ryan, Karl Hazel, Pamla Singh, Vikrant Parihar, Roisin Stack, Anthony O’Connor, Cara Dunne, Garret Cullen, Laurence Egan, Gavin Harewood, Finbar MacCarthy, Susan McKiernan, Hugh Mulcahy, Frank Murray, Stephen Patchett, Juliette Sheridan, Danny Cheriyan, Richard Farrell, John Keohane, Orlaith Kelly, Deirdre McNamara, Barbara Ryan, Colm O’Morain, Subhasish Sengupta, Aoibhlinn O’Toole, Martin Buckley, Jane McCarthy, Glen Doherty, David Kevans & Eoin Slattery. (2020) Irish data on the safety and efficacy of vedolizumab in the treatment of inflammatory bowel disease. Scandinavian Journal of Gastroenterology 55:7, pages 786-794.
Read now
Renáta Bor, Anna Fábián, Mária Matuz, Zoltán Szepes, Klaudia Farkas, Pál Miheller, Tamás Szamosi, Áron Vincze, Mariann Rutka, Kata Szántó, Anita Bálint, Ferenc Nagy, Ágnes Milassin, Tibor Tóth, Ferenc Zsigmond, Judit Bajor, Katalin Müllner, Lilla Lakner, Mária Papp, Ágnes Salamon, Gábor Horváth, Krisztina Sarang, Eszter Schäfer, Patrícia Sarlós, Károly Palatka & Tamás Molnár. (2020) Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease – A nationwide Hungarian cohort study. Expert Opinion on Biological Therapy 20:2, pages 205-213.
Read now
Pauliina Molander, Helena Kemppainen, Tuire Ilus & Taina Sipponen. (2020) Long-term deep remission during maintenance therapy with biological agents in inflammatory bowel diseases. Scandinavian Journal of Gastroenterology 55:1, pages 34-40.
Read now

Articles from other publishers (20)

Uri Kopylov, Johan Burisch, Shomron Ben-Horin, Fiona Braegger, Alonso Fernández-Nistal, Nuria Lara, Henriette Sophie Heinrich & Stephan R Vavricka. (2023) Impact of Vedolizumab on Extraintestinal Manifestations in Inflammatory Bowel Disease: Results From a Descriptive, Retrospective, Real-world Study. Inflammatory Bowel Diseases 29:11, pages 1713-1722.
Crossref
Fabio Salvatore Macaluso, Marco Ventimiglia & Ambrogio Orlando. (2023) Effectiveness and Safety of Vedolizumab in Inflammatory Bowel Disease: A Comprehensive Meta-analysis of Observational Studies. Journal of Crohn's and Colitis.
Crossref
Silvio Danese, Pravin Kamble, Jin Yang, Jean-Gabriel Le Moine, Shahnaz Khan, Emma Hawe, Christian Agboton, Song Wang & Peter M. Irving. (2022) Systematic Literature Review and Meta-analysis: Real-World Mucosal Healing in Vedolizumab-Treated Patients with Crohn’s Disease. GastroHep 2022, pages 1-12.
Crossref
Andrea Cassinotti, Alberto Batticciotto, Marco Parravicini, Maurizio Lombardo, Paolo Radice, Claudio Camillo Cortelezzi, Simone Segato, Federico Zanzi, Antonella Cappelli & Sergio Segato. (2022) Evidence-based efficacy of methotrexate in adult Crohn’s disease in different intestinal and extraintestinal indications. Therapeutic Advances in Gastroenterology 15, pages 175628482210858.
Crossref
Patrick F van Rheenen, Marina Aloi, Amit Assa, Jiri Bronsky, Johanna C Escher, Ulrika L Fagerberg, Marco Gasparetto, Konstantinos Gerasimidis, Anne Griffiths, Paul Henderson, Sibylle Koletzko, Kaija-Leena Kolho, Arie Levine, Johan van Limbergen, Francisco Javier Martin de Carpi, Víctor Manuel Navas-López, Salvatore Oliva, Lissy de Ridder, Richard K Russell, Dror Shouval, Antonino Spinelli, Dan Turner, David Wilson, Eytan Wine & Frank M Ruemmele. (2021) The Medical Management of Paediatric Crohn’s Disease: an ECCO-ESPGHAN Guideline Update. Journal of Crohn's and Colitis 15:2, pages 171-194.
Crossref
Carl Eriksson, Sara Rundquist, Vyron Lykiardopoulos, Ruzan Udumyan, Per Karlén, Olof Grip, Charlotte Söderman, Sven Almer, Erik Hertervig, Jan Marsal, Jenny Gunnarsson, Carolina Malmgren, Jenny Delin, Hans Strid, Mats Sjöberg, David Öberg, Daniel Bergemalm, Henrik Hjortswang & Jonas Halfvarson. (2021) Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study. Therapeutic Advances in Gastroenterology 14, pages 175628482110233.
Crossref
Scott D. Lee, Anand Singla & Kindra Clark‐Snustad. (2021) Standard and modified vedolizumab dosing is effective in achieving clinical and endoscopic remission in moderate‐severe Crohn’s disease. GastroHep 3:1, pages 26-36.
Crossref
Renske Wilhelmina Maria Pauwels, Annemarie Charlotte Vries & Christien Janneke Woude. (2020) Fecal calprotectin is a reliable marker of endoscopic response to vedolizumab therapy: A simple algorithm for clinical practice. Journal of Gastroenterology and Hepatology 35:11, pages 1893-1901.
Crossref
Xu Teng, Yuming Yang, Lu Liu, Lijuan Yang, Jie Wu, Mei Sun & Lingfen Xu. (2020) Evaluation of inflammatory bowel disease activity in children using serum trefoil factor peptide. Pediatric Research 88:5, pages 792-795.
Crossref
B. Bokemeyer, M. Ghiani, A. Fuchs, B. Deiters, F. Hardtstock, A. Brandes, J. Knop, H. D. Orzechowski & T. Wilke. (2020) Indicators of active disease and steroid dependency in patients with inflammatory bowel diseases not treated with biologics in a German real-world-setting. International Journal of Colorectal Disease 35:8, pages 1587-1598.
Crossref
Petros Zezos, Boyko Kabakchiev, Adam V Weizman, Geoffrey C Nguyen, Neeraj Narula, Kenneth Croitoru, A Hillary Steinhart & Mark S Silverberg. (2020) Ulcerative Colitis Patients Continue to Improve Over the First Six Months of Vedolizumab Treatment: 12-Month Clinical and Mucosal Healing Effectiveness. Journal of the Canadian Association of Gastroenterology 3:2, pages 74-82.
Crossref
Bharati Kochar, Yue Jiang, Aaron Winn, Edward L Barnes, Christopher F Martin, Millie D Long & Michael D Kappelman. (2019) The Early Experience With Vedolizumab in the United States. Crohn's & Colitis 360 1:3.
Crossref
Kellyn Moran, Kyle Null, Zhongwen Huang, Trevor Lissoos & Sunanda Kane. (2019) Retrospective Claims Analysis Indirectly Comparing Medication Adherence and Persistence Between Intravenous Biologics and Oral Small-Molecule Therapies in Inflammatory Bowel Diseases. Advances in Therapy 36:9, pages 2260-2272.
Crossref
Gabriele Dragoni, Siro Bagnoli, Marco Le Grazie, Claudia Campani, Francesca Rogai, Natalia Manetti, Carolina Bensi, Giuseppe Macrì, Andrea Galli & Monica Milla. (2019) Long‐term efficacy and safety of vedolizumab in patients with inflammatory bowel diseases: A real‐life experience from a tertiary referral center. Journal of Digestive Diseases 20:5, pages 235-242.
Crossref
Laurent Peyrin-Biroulet, Silvio Danese, Marjorie Argollo, Lieven Pouillon, Spyros Peppas, Marien Gonzalez-Lorenzo, Theodore Lytras & Stefanos Bonovas. (2019) Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn’s Disease or Ulcerative Colitis: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 17:5, pages 838-846.e2.
Crossref
Tero Ylisaukko-oja, Saku Torvinen, Jaakko Aaltonen, Heikki Nuutinen, Timo Blomster, Airi Jussila, Markku Pajala, Kimmo Salminen, Veikko Moilanen, Kalle Hakala, Mikko Kellokumpu, Kari Toljamo, Henna Rautiainen, Juha Kuisma, Markku Peräaho, Pauliina Molander, Jouni Silvennoinen, Ville Liukkonen, Hans Henricson, Jyrki Tillonen, Mirva Esterinen, Christian Nielsen, Eija Hirsi, Margus Lääne, Ulla-Maija Suhonen, Ilkka Vihriälä, Petri Mäkelä, Mika Puhto, Jari Punkkinen, Hannu Sulonen, Sauli Herrala, Jari Jokelainen, Klaus Tamminen & Taina Sipponen. (2019) Characterization of inflammatory bowel disease management by vedolizumab and concomitant treatments in real-life clinical practice. Biologicals 58, pages 50-56.
Crossref
Marco Vincenzo Lenti, Scott Levison, Elena Eliadou, Robert Willert, Karen Kemp, Anna Carter, Catherine Stansfield, Arash Assadsangabi, Salil Singh, Ben Crooks, Suzanne Tattersall, Francesca Fairhurst, Catherine Kenneth, Sreedhar Subramanian, Chris Probert, Daniel Storey, Belle Gregg, Paul Smith, Eleanor Liu, Jimmy K. Limdi, Alex Johnston, Peter John Hamlin & Christian P. Selinger. (2018) A real-world, long-term experience on effectiveness and safety of vedolizumab in adult patients with inflammatory bowel disease: The Cross Pennine study. Digestive and Liver Disease 50:12, pages 1299-1304.
Crossref
Marisa Iborra, Belén Beltrán, Nuria Maroto, Pablo Navarro-Cortés, Maia Boscá-Watts, Isabel Ferrer-Bradley, Natalia García-Morales, Esteban Sáez-González, Joaquín Hinojosa, Miguel Mínguez & Pilar Nos. (2018) Vedolizumab, una opción en pacientes con enfermedad inflamatoria intestinal intolerantes a tiopurinas y refractarios a biológicos. Gastroenterología y Hepatología 41:9, pages 535-543.
Crossref
Marisa Iborra, Belén Beltrán, Nuria Maroto, Pablo Navarro-Cortés, Maia Boscá-Watts, Isabel Ferrer-Bradley, Natalia García-Morales, Esteban Sáez-González, Joaquín Hinojosa, Miguel Mínguez & Pilar Nos. (2018) Vedolizumab, an option in patients with inflammatory bowel disease intolerant to thiopurines and refractory to biological agents. Gastroenterología y Hepatología (English Edition) 41:9, pages 535-543.
Crossref
Ian C Lawrance & Samba Siva Reddy Pulusu. (2018) Real-world evidence for vedolizumab: Understanding the landscape. Journal of Gastroenterology and Hepatology 33, pages 28-29.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.